Evolent Health Inc. (NYSE:EVH) shares reached a new 52-week high during trading on Tuesday . The company traded as high as $24.72 and last traded at $24.47, with a volume of 98,520 shares changing hands. The stock had previously closed at $24.00.

A number of research analysts have recently commented on EVH shares. Jefferies Group started coverage on Evolent Health in a research report on Tuesday. They set a “buy” rating for the company. FBR & Co started coverage on Evolent Health in a research report on Tuesday, March 29th. They set an “outperform” rating and a $16.00 target price for the company. Leerink Swann reiterated an “outperform” rating and set a $20.00 target price on shares of Evolent Health in a research report on Sunday, July 17th. Canaccord Genuity reiterated a “buy” rating on shares of Evolent Health in a research report on Thursday, May 26th. Finally, Zacks Investment Research upgraded Evolent Health from a “sell” rating to a “hold” rating in a research report on Wednesday, May 18th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Evolent Health presently has a consensus rating of “Buy” and an average target price of $21.00.

The firm’s 50 day moving average is $18.95 and its 200-day moving average is $13.14. The company has a market cap of $1.47 billion and a P/E ratio of 6.54.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.03. The company earned $49.50 million during the quarter, compared to analysts’ expectations of $47.40 million. Evolent Health’s revenue was up 33.8% compared to the same quarter last year. Equities research analysts forecast that Evolent Health Inc. will post ($0.62) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Evolent Health stock. Schroder Investment Management Group raised its position in Evolent Health Inc. (NYSE:EVH) by 120.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 355,922 shares of the company’s stock after buying an additional 194,222 shares during the period. Schroder Investment Management Group owned about 0.60% of Evolent Health worth $4,310,000 at the end of the most recent reporting period.

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.